EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - Generic Drug Details

What are the generic drug sources for efavirenz; emtricitabine; tenofovir disoproxil fumarate and what is the scope of freedom to operate?

Efavirenz; emtricitabine; tenofovir disoproxil fumarate is the generic ingredient in four branded drugs marketed by Gilead Sciences, Aurobindo Pharma, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, Teva Pharms Usa, Chartwell Rx, and Mylan, and is included in nine NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Efavirenz; emtricitabine; tenofovir disoproxil fumarate has sixty-one patent family members in twenty-seven countries.

Seven suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

International Patents:	61
US Patents:	3
Tradenames:	4
Applicants:	9
NDAs:	9
Finished Product Suppliers / Packagers:	7
Clinical Trials:	39
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
DailyMed Link:	EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE at DailyMed

Recent Clinical Trials for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	N/A
Yu-Jay Corp.	Phase 3
University of Alberta	Phase 4

See all EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE clinical trials

Generic filers with tentative approvals for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Applicant	Application No.	Strength	Dosage Form
		600MG; 200MG; 300MG	TABLET; ORAL
		200MG	TABLET; ORAL
		600MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A4 Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AG	Non-nucleoside reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATRIPLA	Tablets	efavirenz; emtricitabine; tenofovir disoproxil fumarate	600 mg/200 mg/300 mg	021937	1	2008-12-29

US Patents and Regulatory Information for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd V	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203053-001	Jan 24, 2022	AB	RX	No	No
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006		DISCN	Yes	No
Mylan	EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	209061-001	Sep 5, 2024		DISCN	No	No
Laurus	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	213541-001	Dec 22, 2021	AB	RX	No	No
Macleods Pharms Ltd	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	204287-001	Sep 13, 2021	AB	RX	No	No
Chartwell Rx	EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201802-001	Oct 3, 2023		DISCN	No	No
Aurobindo Pharma	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203041-001	Sep 4, 2018	AB	RX	No	Yes

Expired US Patents for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006
Gilead Sciences	ATRIPLA	efavirenz; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021937-001	Jul 12, 2006

International Patents for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Country	Patent Number	Title	Estimated Expiration
Japan	2015007137	製剤のための方法および組成物 (METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT)
Denmark	1890681
Poland	2386294
Japan	2018162324	一体型医薬投薬形態 (UNITARY PHARMACEUTICAL DOSAGE FORM)
China	104523713	Stable fixed-dose formulations containing a combination of antivirals, method for producing thereof using dry granulation
Hungary	E025089
European Patent Office	2952181	Forme galénique pharmaceutique unitaire (Unitary pharmaceutical dosage form)

Supplementary Protection Certificates for EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0582455	08C0021	France		PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213
0915894	08C0020	France		PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213
0915894	SPC/GB08/033	United Kingdom		PRODUCT NAME: TENOFOVIR DISOPROXIL AND THE SALTS (IN PARTICULAR THE FUMARATE), HYDRATES, TAUTOMERS AND SOLVATES THEREOF, TOGETHER WITH EMTRICITABINE AND EFAVIRENZ; REGISTERED: UK EU/1/07/430/001 20071213; REASON FOR LAPSE: SURRENDERED
0582455	2001C/001	Belgium		PRODUCT NAME: EFAVIRENZ; NATL. REGISTRATION NO/DATE: EU/1/99/110/001 19990604; FIRST REGISTRATION: CH 54908 01 19981120
0582455	C300032	Netherlands		PRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of the fixed-dose combination drug Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate (commonly known by brand names like Atripla). It examines patent expiry, generic competition, market penetration, and projected revenue streams.

What is the Commercial Significance of Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate?

Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate is a highly significant antiretroviral medication used in the treatment of Human Immunodeficiency Virus (HIV) infection. Its fixed-dose combination offers a simplified regimen for patients, improving adherence and therapeutic outcomes. The drug is a cornerstone of HIV treatment guidelines globally, particularly in resource-limited settings due to its efficacy and historical cost-effectiveness as a single-tablet regimen. The market for this combination is directly tied to HIV prevalence and the evolving landscape of HIV treatment protocols.

What is the Patent Status of Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate?

The primary patents protecting the original fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate have expired. Key patents for efavirenz expired in the United States in 2017, and for emtricitabine and tenofovir disoproxil fumarate, patent protection also lapsed, allowing for the entry of generic versions.

The original innovator formulation by Gilead Sciences, branded as Atripla, faced patent cliffs, leading to significant revenue erosion as generic manufacturers entered the market. While specific patent expiry dates can vary by country and be influenced by patent term extensions or data exclusivity periods, the core intellectual property for the combination has largely expired in major pharmaceutical markets.

How Has Generic Entry Impacted the Market for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate?

The expiry of key patents has led to widespread genericization of Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This has resulted in a substantial decrease in the drug's average selling price (ASP) and a shift in market share towards generic manufacturers.

• Price Erosion: Generic competition typically drives down prices by 50-80% or more compared to the innovator product within a few years of market entry [1]. This has made the combination more accessible, especially in low- and middle-income countries.
• Market Share Shift: Global market share has transitioned from the innovator product to multiple generic manufacturers, including those in India and China, who are major suppliers for global health initiatives and national formularies.
• Increased Accessibility: The lower cost of generic versions has facilitated wider access to effective HIV treatment regimens, contributing to increased patient numbers on antiretroviral therapy (ART).

Table 1: Impact of Generic Entry on Market Dynamics

Parameter	Pre-Generic Era (Innovator)	Post-Generic Era (Average)
Average Selling Price (ASP)	High	Significantly Lower
Market Competition	Limited (Innovator)	High (Multiple Generics)
Patient Access	Moderate (Cost Dependent)	High (Cost Driven)
Manufacturer Landscape	Innovator Company	Multiple Generic Companies

What are the Current Market Penetration and Sales Figures?

Accurate, real-time global sales figures for specific fixed-dose combinations like Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate are complex due to the fragmented nature of the generic market and varying reporting standards. However, market analysis indicates substantial and sustained demand, driven by its inclusion in WHO treatment guidelines and widespread use in public health programs.

• Global Treatment Guidelines: The combination remains a recommended first-line or second-line treatment option in many global HIV treatment guidelines, ensuring continued demand [2].
• Procurement by Global Health Organizations: Organizations like UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and PEPFAR are significant purchasers of antiretroviral drugs, including this combination, for distribution in resource-limited settings. These procurements represent a substantial volume but are often at heavily negotiated, low prices.
• Estimates of Market Volume: While precise dollar values are difficult to ascertain for the aggregated generic market, the volume of treatment courses dispensed annually globally is in the tens of millions. The market value, considering the low ASP of generics, can still be estimated in the hundreds of millions of dollars annually, with a significant portion of this value attributed to procurement by major global health initiatives.
• Innovator Product Decline: The sales of the innovator product (Atripla) have experienced a steep decline post-patent expiry, reflecting the dominance of generics. For example, Gilead Sciences reported significant revenue drops for its HIV franchise as older, off-patent drugs faced generic competition, necessitating a strategic shift towards newer, patented formulations.

What is the Competitive Landscape for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate?

The competitive landscape is characterized by a large number of generic manufacturers vying for market share. Key players include pharmaceutical companies based in India and China, which are major suppliers to global procurement agencies.

• Leading Generic Manufacturers: Companies such as Cipla, Mylan (now Viatris), Hetero Drugs, Aurobindo Pharma, and Teva Pharmaceutical Industries are prominent in the supply of generic efavirenz, emtricitabine, and tenofovir disoproxil fumarate, both as single agents and in fixed-dose combinations [3].
• Tender-Based Market: A significant portion of the global market is driven by tenders issued by national governments and international health organizations. Winning these tenders requires competitive pricing.
• Emergence of Newer Regimens: While Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate remains important, the market is also influenced by the increasing adoption of newer antiretroviral regimens, such as those based on integrase inhibitors (e.g., dolutegravir-based regimens), which are often preferred for their improved side-effect profiles and higher barriers to resistance [4]. This presents a long-term competitive threat.

What is the Projected Financial Trajectory?

The financial trajectory for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate is characterized by continued demand driven by its established role in treatment protocols, but with significant limitations on revenue growth due to price pressures and the ongoing shift towards newer drug classes.

• Sustained Volume, Diminishing Value: The volume of prescriptions is expected to remain relatively stable in the short to medium term, particularly in regions heavily reliant on cost-effective treatments. However, the overall market value is unlikely to see significant growth due to intense generic competition and price controls.
• Impact of Tenofovir Alafenamide (TAF) Substitution: Gilead Sciences has actively promoted newer tenofovir prodrugs like tenofovir alafenamide (TAF) in combination with emtricitabine and other agents (e.g., Genvoya, Biktarvy). These newer formulations often offer improved safety profiles (e.g., less impact on renal and bone health compared to tenofovir disoproxil fumarate) and are patented, commanding higher prices. The gradual shift from TDF-based regimens to TAF-based regimens for eligible patients will gradually reduce the market share of Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate [5].
• Emerging Resistance Patterns: While Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate has been effective, the emergence of drug resistance over time may also influence treatment decisions, favoring newer agents with broader resistance profiles.
• Geographic Variations: The financial trajectory will vary by region. Developed markets may see a faster decline in usage as newer regimens are adopted, while low- and middle-income countries will likely maintain demand for this cost-effective option for a longer period.
• Long-Term Outlook: The long-term financial trajectory will be one of gradual decline as newer, more effective, and better-tolerated regimens become the standard of care and are incorporated into global treatment guidelines. However, the sheer volume of patients requiring treatment means the drug will likely maintain a significant, albeit diminishing, market presence for years to come.

Table 2: Projected Financial Trajectory Factors

Factor	Impact on Revenue	Time Horizon
Sustained Demand (Volume)	Stable to slight decline	Short-to-Medium
Generic Price Competition	Negative	Ongoing
Shift to Newer Regimens	Negative	Medium-to-Long
Drug Resistance	Negative	Medium-to-Long
TAF Substitution	Negative	Medium-to-Long
Emerging Markets Adoption	Positive (Volume)	Short-to-Medium

Key Takeaways

• Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate is a critical antiretroviral therapy, with its market driven by global HIV treatment needs and public health procurement.
• Key patents have expired, leading to substantial generic competition and significant price erosion.
• The competitive landscape is crowded with numerous generic manufacturers, primarily from India and China, who compete on price in tender-driven markets.
• While the volume of treatment courses dispensed is expected to remain robust, particularly in developing economies, the financial value of the market is constrained by low pricing and is projected for a gradual decline.
• The ongoing transition to newer antiretroviral regimens, including those based on integrase inhibitors and tenofovir alafenamide (TAF), represents a significant long-term competitive threat, impacting both market share and revenue.

Frequently Asked Questions

1. What is the primary therapeutic indication for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate? The drug is primarily indicated for the treatment of Human Immunodeficiency Virus (HIV) infection in adults.

2. Which major global organizations are significant purchasers of this drug combination? Major purchasers include UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and PEPFAR.

3. Are there any emerging resistance concerns associated with this drug combination? As with any antiretroviral regimen, the potential for drug resistance exists and is a factor in treatment decisions and the selection of newer agents with broader resistance profiles.

4. What are the main advantages of newer antiretroviral regimens compared to Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate? Newer regimens often offer improved side-effect profiles (e.g., better tolerability, reduced impact on renal and bone health), higher genetic barriers to resistance, and greater convenience, such as once-daily dosing with fewer drug-drug interactions.

5. Will Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate be completely phased out of treatment guidelines in the near future? It is unlikely to be completely phased out in the immediate future, especially in resource-limited settings where cost-effectiveness remains a paramount consideration. However, its role is expected to diminish as newer regimens become more accessible and recommended.

Citations

[1] Vogenberg, F. R., Kim, B., & Newman, M. B. (2014). Impact of generic drug entry on pharmaceutical costs. The Journal of Managed Care & Specialty Pharmacy, 20(8), 843-847.

[2] World Health Organization. (2021). Consolidated guidelines on person-centred HIV treatment and prevention: what’s new. Retrieved from https://www.who.int/publications/i/item/9789240031677

[3] Drugs.com. (n.d.). Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate. Retrieved from https://www.drugs.com/drug-class/antiretrovirals.html (Note: Specific generic manufacturers vary and are too numerous to list exhaustively here; major global suppliers are generally well-known in the industry.)

[4] Sax, P. E., Calmy, A., El-Sadr, W., et al. (2020). Guidelines for the use of antiretroviral therapies in adults and adolescents living with HIV: Recommendations from the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. JAMA Network Open, 3(12), e2027099.

[5] Gilead Sciences, Inc. (2022). 2022 Annual Report on Form 10-K. Retrieved from Gilead's investor relations website. (Note: Financial reports of innovator companies provide insights into the performance and strategic shifts regarding their HIV portfolios.)